Sangamo Therapeutics, Inc. SGMO Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sangamo Therapeutics, Inc. SGMO

SGMO 0.572

-1.4%

Oct 30 3:59 PM EDT

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: PLegee	1/14/2013 9:01:45 PM
	Read Replies (1) of 368

1.86M shares traded today, new 52 week high, 6X normal volume, a 17% increase in price. No news to account for the big day as of this time, seems to me that a big fund started to establish a position and then others joined the frenzy. At 10 am EST, volume appeared fairly normal with the stock only marginally above the previous close. Shortly thereafter, a major volume spike occurred (I haven't pulled the block trades yet) which seem to fuel the stock momentum for the remainder of the day. Volume in the 2nd half of the day continued to increase with the last half hour showing numerous high volume trades. Possibly the recent and impressive presentation at the JPM Healthcare Conference finally incited some funds to act. Regardless, the recent Shire deal along with a rejuvenated board (since the Bill Ringo addition in 2010; undoubtedly the driving force in the Shire deal) proves to me that the "new" SGMO is on the right track. The company seems to have a sense of purpose that it had lacked in the past. The near term catalyst is obviously the HIV update that will be disclosed in the first half of 2013; this will be the real determinant of where this company is headed near term. SGMO needs to continue to operate with the same sense of urgency it has embraced as of late. Talens, CRSPRS and who knows what other form of gene editing is currently being developed, and beginning to appear on the horizon. We have the IP locked up for ZFN, a minimum two year lead in development; lets use it to our/patient advantage.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next